Merit Medical Systems Inc. (MMSI) stock surged 5.85% in pre-market trading on Wednesday after the company reported better-than-expected Q4 2024 earnings results. The medical device maker's quarterly revenue and earnings exceeded Wall Street analysts' estimates, driven by strong sales growth across its key business segments.
Merit Medical's Q4 revenue jumped 9.4% year-over-year to $355.2 million, beating consensus estimates of $351.9 million. The company's non-GAAP earnings per share of $0.93 also comfortably surpassed analysts' expectations of $0.83, representing a 12% beat. Merit's robust performance was fueled by solid growth in its Cardiovascular and Endoscopy segments, which saw revenue increase by 7.1% and 87.9% respectively compared to the prior year.
Additionally, Merit Medical's outlook for fiscal 2025 remained optimistic, with the company projecting revenue growth of around 9.1% and non-GAAP earnings per share guidance in the range of $3.58 to $3.70. The company's strong Q4 results and positive forward guidance were well-received by investors, leading to the significant pre-market stock surge.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。